[ad_1]
British-Swedish pharmaceutical company AstraZeneca, which is working on a coronavirus vaccine, said it has found a “successful formula” for it.
According to CEO Pascal Sorio, in November the drug showed an average efficiency of protection against the virus of 70%, writes The Sunday Times. Subsequent trials should show that this vaccine can compete with Pfizer and Moderna, he said.
AstraZeneca, which is developing AZD1222 with the University of Oxford, has identified a formula that can improve its effectiveness, Sorio said.
“We think we have identified a formula for success and a way to achieve the same high performance as everyone else after two doses,” he said.
The company representative promised to release the details later.
The effectiveness of the new vaccine was determined in mid-November during special tests, the newspaper writes. Two variants of drug delivery were tested. In a group of 2.7,000 volunteers, the subjects first received half a dose of the drug and, a month later, the full dose. The efficiency in this case reached 90%. 9,000 subjects in the other group received double the full dose; the effectiveness was 62%. Therefore, the average efficiency is 70%.
Sorio said the new drug has characteristics that “meet the criteria established by regulators around the world.” He also added that AZD1222 protects against severe forms of coronavirus with 100% efficiency.
The CEO of the company expressed confidence that subsequent trials of the vaccine will show that it “can compete with drugs from Pfizer and BioNTech.”
AstraZeneca also plans to conduct trials to see if the vaccine is capable of protecting against the “British strain” of the coronavirus, he said.
According to Sorio, the new vaccine will be easier to transport than the mentioned drugs. The latter need very low temperatures, and a normal refrigerator is suitable for AZD1222. The cost for a dose of AstraZeneca’s vaccine will be $ 3-5, he said.
It is known that the new vaccine will begin shipping to countries around the world from January 4, 2021. During the first two weeks of distribution, the vaccine will be administered. two million willing.
The drug is expected to be approved by the UK’s National Medicines Regulatory Authority.
Ukraine, to immunize the population against COVID-19, is likely to receive the AstraZeneca vaccine.
Previously, OBOZREVATEL reported that, according to the Warp Speed project’s chief scientific advisor, Dr. Monsef Sloughi, inaction Pfizer COVID-19 causes more allergic reactionsthan other drugs.
As of Dec. 22, there were six reported cases, he said, and the frequency exceeds what would be expected from other vaccines.
